Overweight Clinical Trials in Shavano Park, Texas

9 recruitingShavano Park, Texas

Showing 19 of 9 trials

Recruiting
Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

ObesityOverweightSleep Apnea, Obstructive
Eli Lilly and Company800 enrolled123 locationsNCT07369011
Recruiting
Phase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

OsteoarthritisOverweight or Obesity
Eli Lilly and Company900 enrolled154 locationsNCT07353931
Recruiting
Phase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

ObesityOverweight
Eli Lilly and Company900 enrolled178 locationsNCT07392190
Recruiting
Phase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

ObesityOverweight
Eli Lilly and Company600 enrolled80 locationsNCT06972459
Recruiting
Phase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

ObesityOverweightType 2 Diabetes
Eli Lilly and Company1,200 enrolled80 locationsNCT06993792
Recruiting
Phase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

ObesityOverweight
Novo Nordisk A/S460 enrolled119 locationsNCT07253285
Recruiting
Phase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

ObesityDiabetes Mellitus, Type 2Overweight
Eli Lilly and Company200 enrolled38 locationsNCT07215559
Recruiting
Phase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

ObesityOverweightType 2 Diabetes
Eli Lilly and Company600 enrolled77 locationsNCT06972472